Trial Profile
Randomized Phase I/II Study to Evaluate the Safety and Immunogenicity of MG 1109 (Egg-based, Pre-pandemic Influenza(H5N1) Vaccine); Administered Intramuscularly in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GC Pharma
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 25 Aug 2011 New source identified and integrated (Korean Clinical Trials Register KCT0000119)
- 12 Jul 2011 New trial record